Analysts Offer Insights on Healthcare Companies: Rezolute (RZLT) and Boston Scientific (BSX)
There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Rezolute (RZLT) and Boston Scientific (BSX) with bullish sentiments.
Claim 55% Off TipRanks
- Unlock powerful investing tools with TipRanks Premium to make smarter, more confident investment decisions
- Subscribe to TipRanks Smart Investor Newsletter, and discover new investing opportunities with data-backed stock picks
Rezolute (RZLT)
H.C. Wainwright analyst Douglas Tsao reiterated a Buy rating on Rezolute today and set a price target of $5.00. The company’s shares closed last Wednesday at $4.73.
According to TipRanks.com, Tsao is a 5-star analyst with an average return of
Currently, the analyst consensus on Rezolute is a Strong Buy with an average price target of $8.43.
See today’s best-performing stocks on TipRanks >>
Boston Scientific (BSX)
Needham analyst Michael Matson maintained a Buy rating on Boston Scientific today and set a price target of $57.00. The company’s shares closed last Wednesday at $46.32.
According to TipRanks.com, Matson is a 4-star analyst with an average return of
Currently, the analyst consensus on Boston Scientific is a Strong Buy with an average price target of $68.42, implying a 60.3% upside from current levels. In a report issued on July 14, TipRanks – DeepSeek also upgraded the stock to Buy with a $49.00 price target.
Read More on RZLT:
Disclaimer & DisclosureReport an Issue
- What the $10B Crinetics Deal & $2.9B Soleno Acquisition Might Say About Palatin’s Rare-Obesity Opportunity
- Rezolute price target raised to $11, named a Best Idea at Guggenheim
- Yum! Brands upgraded, Chipotle downgraded: Wall Street’s top analyst calls
- Rezolute price target raised to $14 from $10 at Maxim
- Rezolute price target raised to $6 from $5 at Wedbush
